AMPH

Amphastar Pharmaceuticals, Inc. develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal pharmaceuticals. Headquartered in Rancho Cucamonga, California, the company operates through two segments: finished pharmaceutical products and active pharmaceutical ingredients (API). Amphastar's portfolio includes critical medications such as enoxaparin sodium injection (a generic version of Lovenox), naloxone for opioid overdose reversal, epinephrine for severe allergic reactions, and lidocaine for pain management. The company also produces Primatene MIST, the only FDA-approved over-the-counter asthma inhaler available without a prescription in the United States. With manufacturing facilities in California, China, and France, Amphastar supplies hospitals, clinics, and pharmacies primarily across the domestic market while expanding its international presence. The company employs approximately 2,000 people and generates annual revenues exceeding $500 million. Recent developments include the expansion of its biosimilar pipeline, FDA approvals for additional generic injectables, and capacity investments to meet growing demand for emergency medications. Amphastar maintains vertical integration through its API production capabilities, which provides supply chain control and cost advantages. The company continues to focus on developing complex generics and specialty products in therapeutic areas with limited competition, positioning itself in niche segments of the pharmaceutical industry.